Emmaus Life Sciences Changes Fiscal Year End

TL;DR

Emmaus Life Sciences (EMMA) is changing its fiscal year end to Dec 31, effective May 23.

AI Summary

Emmaus Life Sciences, Inc. filed an 8-K on May 28, 2024, reporting a change in its fiscal year end to December 31st. This change is effective as of May 23, 2024. The company was formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC.

Why It Matters

A change in fiscal year end can impact reporting schedules and financial comparisons for investors. This filing clarifies Emmaus Life Sciences' new reporting cycle.

Risk Assessment

Risk Level: low — This filing is administrative and does not involve significant financial transactions or operational changes.

Key Players & Entities

• Emmaus Life Sciences, Inc. (company) — Registrant
• May 23, 2024 (date) — Effective date of fiscal year change
• December 31 (date) — New fiscal year end
• MYnd Analytics, Inc. (company) — Former company name
• CNS RESPONSE, INC. (company) — Former company name
• STRATIVATION, INC. (company) — Former company name

FAQ

Filing Documents

• ea0206971-8k_emmaus.htm (8-K) — 27KB
• ea020697101ex3-1_emmaus.htm (EX-3.1) — 5KB
• 0001213900-24-047151.txt ( ) — 201KB
• emma-20240523.xsd (EX-101.SCH) — 3KB
• emma-20240523_lab.xml (EX-101.LAB) — 33KB
• emma-20240523_pre.xml (EX-101.PRE) — 22KB
• ea0206971-8k_emmaus_htm.xml (XML) — 3KB

03 Amendments to Articles of Incorporation or Bylaws; Change

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At a meeting of the Board of Directors of Emmaus Life Sciences, Inc. ("we," "our," "us," "Emmaus" or the "company") held on May 23, 2024, our Board of Directors adopted an amendment (the "Amendment") to our Amended and Restated By-Laws (the "By-Laws") to provide that, subject to certain exceptions, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the company, (ii) any action based upon a violation of a duty owed by any current or former director, officer, employee, agent or stockholder of the company to the company or its stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our Certificate of Incorporation or the By-Laws, or as to which the Delaware General Corporation Law confers jurisdiction upon the Court of Chancery, or (iv) any action asserting a claim governed by the internal affairs doctrine. The Amendment also designates the U.S. federal district courts as the sole and exclusive forums for the resolution of any complaint asserting a cause of action under the Securities Act of 1933, as amended, and provides that any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the company shall be deemed to have notice of and consented to the provisions of the Amendment, which was effective upon its adoption by the Board of Directors. The foregoing description of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment, a copy of which is included attached as Exhibit 3.1 to this Current Report and incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which information is incorporated herein by reference. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 28, 2024 Emmaus Life Sciences, Inc. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2 INDEX TO EXHIBITS Exhibit Number Description 3.1 Amendment No. 1 to Amended and Restated By-Laws 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR